volrustomig + ramucirumab + carboplatin + pemetrexed

This is an investigational four-drug combination regimen comprising **volrustomig** (a novel bispecific monoclonal antibody also known as MEDI5752, targeting programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)), **ramucirumab** (a monoclonal antibody targeting vascular endothelial growth factor receptor 2 (VEGFR-2)), **carboplatin** (a platinum-based chemotherapeutic agent that forms DNA crosslinks), and **pemetrexed** (a multitargeted antifolate antineoplastic agent that inhibits multiple enzymes involved in folate metabolism and DNA synthesis). Volrustomig is under development by AstraZeneca for the treatment of solid tumors, with active evaluation in non-squamous non-small cell lung cancer (NSCLC) and other cancers. This specific four-drug regimen is being studied in a phase II trial for treatment-naïve patients with advanced or metastatic non-squamous NSCLC, administered via intravenous infusion[1][3][5][9].